课题基金 / 基金详情

IL2-based Immunotherapy for Type 2 Diabetes

IL2-based Immunotherapy for Type 2 Diabetes
基于 IL2 的 2 型糖尿病免疫疗法
批准号:
9135661
负责人:
RIDONG CHEN
金额:
$29.92万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-05-01 至 2017-08-31

项目摘要

项目成果

RIDONG CHEN的其他基金

相似基金

相关文献

中文摘要
翻译

英文摘要
 DESCRIPTION (provided by applicant): Principal Investigator/Program Director (Last, First, Middle: Chen, Ridong Abstract Type-2 diabetes (T2D) is a leading cause of cardiovascular disease, renal failure, blindness, amputations and hospitalization. Up to 80% of T2D patients are overweight or obese, which induces chronic, low-grade inflammation of adipose tissue and promotes insulin resistance and T2D. Moreover, weight gain is the common side-effect of older anti-diabetic drugs. Current therapies are not a cure and require daily administration. Hence, novel therapy that improves glucose control while simultaneously reducing body weight is urgently needed. CD4+CD25+Foxp3+ regulatory T cells (Treg) modulate inflammation and insulin resistance. Very interestingly, Treg cells with a unique phenotype are highly enriched in the visceral adipose tissue (VAT) of normal animals, but their numbers are strikingly and specifically reduced in insulin-resistant models of obese animals. Importantly, decreased numbers of Treg are also found in obese human omental. Interleukin-2 (IL-2) is the key cytokine for the generation, survival, and function of Treg by direct binding to its high affinity receptor. Hence, restoration of VAT Treg cells with low-dose IL2 may offer a novel strategy for mitigating obesity related low-grade inflammation and reversing insulin resistance and T2D. We have designed an IL2-based therapy that will enable selective stimulation of Tregs. In the proposed Phase I SBIR study, we will determine whether weekly treatment for 4 weeks leads to improvement of insulin sensitivity and glucose control, while reducing excessive body weight gain in the T2D models of obese db/db mice and diet-induced obese mice. The long-term goal of this project is to develop a novel treatment (weekly or bi-weekly) for T2D, alone or in combination with current therapies, to improve glucose homeostasis and attenuate diabetes-associated complications while simultaneously reducing excessive body weight gain.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Multi-functional anti-thrombotic therapy for coronary microvascular obstruction
  • 批准号:
    10696319
  • 项目类别:
  • 资助金额:
    $158.2万
  • 财政年份:
    2023
  • 负责人:
    RIDONG CHEN
  • 依托单位:
Peripherally Acting Analgesic for Osteoarthritis Pain
  • 批准号:
    10249564
  • 项目类别:
  • 资助金额:
    $25.96万
  • 财政年份:
    2021
  • 负责人:
    RIDONG CHEN
  • 依托单位:
Synergistic Efficacy of an Interleukin 2 Analog and Antitumor Antigen Antibody
  • 批准号:
    9905448
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2019
  • 负责人:
    RIDONG CHEN
  • 依托单位:
Immunomodulatory Therapy for Neuropathic Pain
  • 批准号:
    10684821
  • 项目类别:
  • 资助金额:
    $50.13万
  • 财政年份:
    2018
  • 负责人:
    RIDONG CHEN
  • 依托单位:
海外基金